175 related articles for article (PubMed ID: 18367229)
1. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.
Polonis VR; Brown BK; Rosa Borges A; Zolla-Pazner S; Dimitrov DS; Zhang MY; Barnett SW; Ruprecht RM; Scarlatti G; Fenyö EM; Montefiori DC; McCutchan FE; Michael NL
Virology; 2008 Jun; 375(2):315-20. PubMed ID: 18367229
[TBL] [Abstract][Full Text] [Related]
2. Impact of host cell variation on the neutralization of HIV-1 in vitro.
Polonis VR; Schuitemaker H; Bunnik EM; Brown BK; Scarlatti G
Curr Opin HIV AIDS; 2009 Sep; 4(5):400-7. PubMed ID: 20048704
[TBL] [Abstract][Full Text] [Related]
3. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
[TBL] [Abstract][Full Text] [Related]
4. Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells.
Chen Q; Nie J; Huang W; Jiao Y; Li L; Zhang T; Zhao J; Wu H; Wang Y
Hum Vaccin Immunother; 2018 Jan; 14(1):199-208. PubMed ID: 28933644
[TBL] [Abstract][Full Text] [Related]
5. HIV sensitivity to neutralization is determined by target and virus producer cell properties.
Mann AM; Rusert P; Berlinger L; Kuster H; Günthard HF; Trkola A
AIDS; 2009 Aug; 23(13):1659-67. PubMed ID: 19581791
[TBL] [Abstract][Full Text] [Related]
6. Measuring HIV neutralization in a luciferase reporter gene assay.
Montefiori DC
Methods Mol Biol; 2009; 485():395-405. PubMed ID: 19020839
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of HIV-1 by antibody.
Sattentau QJ
Curr Opin Immunol; 1996 Aug; 8(4):540-5. PubMed ID: 8794008
[TBL] [Abstract][Full Text] [Related]
8. New virologic reagents for neutralizing antibody assays.
Ochsenbauer C; Kappes JC
Curr Opin HIV AIDS; 2009 Sep; 4(5):418-25. PubMed ID: 20048706
[TBL] [Abstract][Full Text] [Related]
9. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
10. The role of neutralizing antibodies in HIV infection.
Humbert M; Dietrich U
AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
[TBL] [Abstract][Full Text] [Related]
11. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.
Montefiori DC
Curr Protoc Immunol; 2005 Jan; Chapter 12():12.11.1-12.11.17. PubMed ID: 18432938
[TBL] [Abstract][Full Text] [Related]
12. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
Haynes BF; Moody MA; Verkoczy L; Kelsoe G; Alam SM
Hum Antibodies; 2005; 14(3-4):59-67. PubMed ID: 16720975
[TBL] [Abstract][Full Text] [Related]
13. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
14. International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.
Ozaki DA; Gao H; Todd CA; Greene KM; Montefiori DC; Sarzotti-Kelsoe M
PLoS One; 2012; 7(1):e30963. PubMed ID: 22303476
[TBL] [Abstract][Full Text] [Related]
15. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
16. Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay.
Cavacini L; Posner M
AIDS Res Hum Retroviruses; 2004 Apr; 20(4):435-41. PubMed ID: 15157362
[TBL] [Abstract][Full Text] [Related]
17. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.
Todd CA; Greene KM; Yu X; Ozaki DA; Gao H; Huang Y; Wang M; Li G; Brown R; Wood B; D'Souza MP; Gilbert P; Montefiori DC; Sarzotti-Kelsoe M
J Immunol Methods; 2012 Jan; 375(1-2):57-67. PubMed ID: 21968254
[TBL] [Abstract][Full Text] [Related]
18. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.
Sarzotti-Kelsoe M; Bailer RT; Turk E; Lin CL; Bilska M; Greene KM; Gao H; Todd CA; Ozaki DA; Seaman MS; Mascola JR; Montefiori DC
J Immunol Methods; 2014 Jul; 409():131-46. PubMed ID: 24291345
[TBL] [Abstract][Full Text] [Related]
19. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
[TBL] [Abstract][Full Text] [Related]
20. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
